Development of vaccines for Candida albicans: Fighting a skilled transformer

Nature Reviews Microbiology

Volumn 11, Issue 12, 2013, Pages 884-891

  Cassone, Antonio ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CANDIDA ALBICANS VACCINE;

CANDIDA ALBICANS; CANDIDIASIS; COMMENSAL; FUNGAL VIRULENCE; HUMAN; IMMUNE RESPONSE; INFECTION PREVENTION; OPPORTUNISTIC INFECTION; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW;

CANDIDA ALBICANS; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; FUNGAL VACCINES; GENETIC VARIATION; HUMANS; IMMUNE EVASION; VACCINES, SUBUNIT;

EID: 84887876631     PISSN: 17401526     EISSN: 17401534     Source Type: Journal    
DOI: 10.1038/nrmicro3156     Document Type: Review

References (64)

1. Cutler, J. E., Deepe, G. S. & Klein, D. Advances in combating fungal diseases: vaccines on the threshold. Nature Rev. Microbiol. 5, 13-28 (2007). (Pubitemid 44942300)
2. Cassone, A. Fungal vaccines: real progress from real challenge. Lancet Infect. Dis. 8, 114-124 (2008).
3. Cassone, A. & Casadevall, A. Recent progress in vaccines against fungal diseases. Curr. Opin. Microbiol. 15, 1-7 (2012).
4. Edwards, J. E. Fungal cell wall vaccines: an update. J. Med. Microbiol. 61, 895-903 (2012).
5. De Bernardis, F. et al. A virosomal vaccine against candidal vaginitis: immunogenicity, efficacy and safety profile in animal models. Vaccine 30, 4490-4498 (2012).
6. Schmidt, C. S. et al. NDV-3, a recombinant alum-adjuvanted vaccine for Candida and Staphylococcus aureus is safe and immunogenic in healthy adults. Vaccine 30, 7594-7600 (2012).
7. Torosantucci, A. et al. A novel glyco-conjugate vaccine against fungal pathogens. J. Exp. Med. 202, 597-606 (2005). (Pubitemid 41258184)
8. Bromuro, C. et al. ?-glucan-CRM197 conjugates as candidates antifungal vaccines. Vaccine 28, 2615-2623 (2010).
9. Xin, H., Dziadek, S., Bundle, D. R. & Cutler, J. E. Synthetic glycopeptide vaccines combining ?-mannan and peptide epitopes induce protection against candidiasis. Proc. Natl Acad. Sci. USA 105, 13526-13531 (2008).
10. Han, Y. & Rhew, K. Y. Comparison of two Candida mannan vaccines: the role of complement in protection against disseminated candidiasis. Arch. Pharm. Res. 35, 2021-2027 (2012).
11. Cassone, A. & Rappuoli, R. Universal vaccines: shifting to one for many. mBio 1, e00042-10 (2010).
12. Pfaller, M. A. & Diekema, D. J. Epidemiology of invasive mycoses in North America. Crit. Rev. Microbiol. 36, 1-53 (2010).
13. Cassone, A.& Cauda, R. Candida and candidiasis in HIV-infected subjects. Where commensalism, opportunistic behavior and frank pathogenicity lose their borders. AIDS 26, 1457-1472 (2012).
14. Foxman, B., Muraglia, R., Dietz, J., Sobel, J. D. & Wagner, J. Prevalence of recurrent vulvovaginal candidiasis in 5 European countries and the United States: results from an internal panel survey. J. Low. Genit. Tract Dis. 17, 340-345 (2013).
15. Pappas, P. G. Invasive candidiasis. Infect. Dis. Clin. North Am. 20, 485-506 (2006). (Pubitemid 44375119)
16. Diekema, D., Arbefeville, S., Boyken, L., Kroeger, J. & Pfaller, M. The changing epidemiology of healthcare-associated candidemia over three decades. Diagn. Microbiol. Infect. Dis. 73, 45-48 (2012).
17. Klis, F. M., de Koster, C. G. & Brul, S. A mass spectrometric view of the fungal wall proteome. Future Microbiol. 6, 941-951 (2011).
18. Plain, A. et al. Functional analysis of Candida albicans GPI-anchored proteins: roles in cell wall integrity and caspofungin sensitivity. Fungal Genet. Biol. 45, 1404-1414 (2008).
19. LeibundGut-Landman, S., Wutrich, M. & Hohl, T. Immunity to fungi. Curr. Opin. Immunol. 24, 1-10 (2012).
20. Romani, L. Immunity to fungal infections. Nature Rev. Immunol. 11, 275-288 (2011).
21. Gaffen, S. L. Hern?ndez-Santos, N. & Peterson, A. C. IL-17 signaling in host defense against Candida albicans. Immunol. Res. 50, 181-187 (2011).
22. Carvalho, A. et al. Host defense pathways against fungi: the basis for vaccines and immunotherapy. Front. Microbiol. 3, 1-9 (2012).
23. Zelante, T. et al. IL-17/Th17 in anti-fungal immunity: what's new? Eur. J. Immunol. 39, 645-648 (2009).
24. Kaufmann, S. The contribution of immunology to the rational design of novel antibacterial vaccines. Nature Rev. Microbiol. 5, 491-504 (2007). (Pubitemid 46925378)
25. Lin, L. et al. Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice. PLoS Pathog. 5, e1000703 (2009).
26. Spellberg, B. et al. Antibody titer threshold predicts anticandidal vaccine efficacy even though the mechanism of protection is induction of cell-mediated immunity. J. Infect. Dis. 197, 957-971 (2008).
27. Luo, G. et al. Human anti-Als3p antibodies enhance phagocyte-mediated killing of C. albicans and S. aureus and prevent Als3 function. Abstract 178A in: 11th American Society for Microbiology Conference on Candida and Candidiasis (2012).
28. Almond, J. W. Vaccine renaissance. Nature Rev. Microbiol. 5, 479-482 (2007).
29. Kniemeyer, O. Schmidt, A. D., V?disch, M. Wartenberg, D. & Brakhage, A. A. Identification of virulence determinants of the human pathogenic fungi Aspergillus fumigatus and Candida albicans by proteomics. Int. J. Med. Microbiol. 301, 368-377 (2011).
30. Mayer, F. L., Wilson, D. & Hube, B. Candida albicans pathogenicity mechanisms. Virulence 42, 1-10 (2013).
31. Lesiak-Markowicz, I. et al. Candida albicans Hgt1p, a multifunctional evasion molecule: complement inhibitory, CR3 analogue and human immunodeficiency virus-binding molecule. J. Infect. Dis. 204, 802-809 (2009).
32. Luo, S., Hoffmann, R., Sharka, C. & Zipfel, P. E. Glycerol-3-phosphate dehydrogenase 2 is a novel factor H-,factor H-like protein 1-, and plasminogen-binding surface protein of Candida albicans. J. Infect. Dis. 207, 594-603 (2013).
33. Frohner, I. E., Bourgeois, C., Yatsik, K., Mayer, O. & Kuchler, K. Candida albicans cell surface superoxide dismutases degrade host-derived reactive oxygen species to escape innate immunity surveillance. Mol. Microbiol. 71, 240-252 (2009).
34. Cheng, S. et al. Candida albicans dampens host defence by downregulating IL-17 production. J. Immunol. 185, 2450-2457 (2010).
35. Zelante, T. et al. Sensing of mammalian IL-17A regulates fungal adaptation and virulence. Nature Commun. 3, 683-687 (2013).
36. Bromuro, C. et al. Interplay between protective and inhibitory antibodies dictates the outcome of experimentally disseminated candidiasis in recipients of a Candida albicans vaccine. Infect. Immun. 70, 5462-5470 (2002).
37. Cutler, J. E., Corti, M., Lambert, P., Ferris, M. & Xin, H. Horizontal transmission of Candida albicans and evidence for a vaccine response in mice colonized with the fungus. PLoS ONE 6, e22030 (2011).
38. Moffitt, K. L. & Malley, R. Next generation pneumococcal vaccines. Curr. Opin. Immunol. 145, 277-286 (2011).
39. Guiso, N. Bordetella pertussis and pertussis vaccines. Clin. Infect. Dis. 49, 1565-1569 (2009).
40. Amdahl, H. et al. Interactions between Bordetella pertussis and the complement inhibitor factor H. Mol. Immunol. 48, 697-705 (2011).
41. Plotkin, S. A. & Orenstein, W. A. (eds) Vaccines (Saunders, 1999).
42. Liu, M. et al. Immune responses induced by heat-killed Saccharomyces cerevisiae: a vaccine against fungal infection. Vaccine 29, 1745-1753 (2011).
43. Cheng, S., Joosten, L. A. B., Kullberg, B. & Netea, M. G. Interplay between Candida albicans and the mammalian innate host defense. Infect. Immun. 80, 1304-1313 (2012).
44. Nanjappa, S. G., Henninger, E., Wuthrich, M., Gasper, D. J. & Klein, B. S. Tc17 cells mediate vaccine immunity against lethal fungal pneumonia in immune-deficient hosts lacking CD4+T cells. PLoS Pathog. 8, e1002771 (2012).
45. Hung, C. Y., Gonzales, A., Wuthrich, M., Klein, B. S. & Cole, G. T. Vaccine immunity to coccidiodomycosis occurs by early activation of three signal pathways of T helper cell responses (Th1,Th2 and Th17). Infect. Immun. 79, 4511-4522 (2011).
46. Bistoni, F. et al. Evidence for macrophage-mediated protection against lethal Candida albicans infection. Infect. Immun. 51, 668-674 (1986). (Pubitemid 16212149)
47. Saville, S. P. et al. Efficacy of a genetically engineered Candida albicans tet-NRG1 strain as an experimental live attenuated vaccine against hemathogeneously disseminated candidiasis. Clin. Vaccine Immunol. 16, 430-432 (2009).
48. Ahmad, E., Fatima, M. T., Salemeddin, M. & Owais, M. Plasma beads loaded with Candida albicans cytosolic proteins impart protection against the fungal infection in Balb/c mice. Vaccine 30, 6851-6858 (2012).
49. Salgado, P. S. et al. Structural basis for the broad specificity to host-cell ligands by the pathogenic fungus Candida albicans. Proc. Natl Acad. Sci. USA 108, 15775-15779 (2011).
50. Aoki, W. et al. Comprehensive characterization of secreted aspartic proteases encoded by a virulence gene family in Candida albicans. J. Biochem. 150, 431-438 (2011).
51. Villar, C. C. et al. Mucosal tissue invasion by Candida albicans is associated with E-cadherin degradation, mediated by transcription factor Rim101p and protease Sap5p. Infect. Immun. 75, 2126-2135 (2007). (Pubitemid 46744298)
52. Liu, Y. & Filler, S. G. Candida albicans Als3, a multifunctional adhesin and invasin. Eukaryot. Cell 10, 168-173 (2011).
53. Gropp, K. et al. The yeast Candida albicans evades human complement attack by secretion of aspartic proteases. Mol. Immunol. 47, 463-475 (2009).
54. Pietrella, D. et al. Secreted aspartic proteases of Candida albicans activate the NLRP3 inflammasome. Eur. J. Immunol. 43, 679-692 (2013).
55. Vilanova, M. et al. Protection against systemic candidiasis in mice immunized with secreted aspartic proteinase 2. Immunology. 111, 334-342 (2004). (Pubitemid 38365757)
56. Luo, G. et al. Candida albicans Hyr1p confers resistance to neutrophil killing and is a potential vaccine target. J. Infect. Dis. 201, 1718-1728 (2019).
57. Johnson, M. A. & Bundle, D. R. Designing a new antifungal glycoconjugate vaccine. Chem. Soc. Rev. 42, 4327-4344 (2012).
58. Torosantucci, A. et al. Protection by anti-?-glucan antibodies is associated with restricted ?-1,3 glucan binding specificity and inhibition of fungal growth and adherence. PLoS ONE 4, e5392 (2009).
59. Cassone, A. Bromuro, C., Chiani, P. & Torosantucci, A. Hyr1 protein and ?-glucan conjugates as anti-Candida vaccines. J. Infect. Dis. 202, 1930 (2010).
60. Xin, U. et al. Self-adjuvanting glycopeptide conjugate vaccine against disseminated candidiasis. PLoS ONE 7, e35106 (2012).
61. Lipinski, T. et al. Enhanced immunogenicity of a tricomponent mannan tetanus toxoid conjugate vaccine targeted to dendritic cells via dectin-1 by incorporating ?-glucan J. Immunol. 190, 4116-4128 (2013).
62. Li, W. Long, K. & Gao, X. Adjuvanticity of recombinant calreticulin fragment 39-372 in assisting anti-?-glucan IgG responses in T cell deficient mice. Clin. Vacc. Immunol. 20, 582-597 (2013).
63. Cutfield, S. M. et al. The crystal structure of a major secreted aspartic proteinase from Candida albicans in complexes with two inhibitors. Structure 3, 1261-1271 (1995). (Pubitemid 3001424)
64. Calugi, C. et al. Bicyclic peptidomimetics targeting secreted aspartic protease 2 (SAP2) from Candida albicans reveal a constrained inhibitory chemotype. Bioorgan. Med. Chem. 20, 7206-7213 (2012).